Catalyst Pharmaceuticals, Inc. to Post Q4 2017 Earnings of ($0.05) Per Share, SunTrust Banks Forecasts (NASDAQ:CPRX)
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) – Analysts at SunTrust Banks boosted their Q4 2017 EPS estimates for shares of Catalyst Pharmaceuticals in a research note issued to investors on Thursday. SunTrust Banks analyst E. Nash now expects that the biopharmaceutical company will post earnings of ($0.05) per share for the quarter, up from their prior forecast of ($0.06). SunTrust Banks also issued estimates for Catalyst Pharmaceuticals’ FY2018 earnings at ($0.30) EPS, FY2019 earnings at ($0.23) EPS, FY2020 earnings at $0.05 EPS and FY2021 earnings at $0.57 EPS.
Catalyst Pharmaceuticals (NASDAQ:CPRX) last issued its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.01.
Other equities analysts have also issued research reports about the stock. Zacks Investment Research upgraded shares of Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.50 target price for the company in a research report on Monday, May 22nd. Roth Capital set a $5.00 target price on shares of Catalyst Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday. Finally, Piper Jaffray Companies set a $6.00 target price on shares of Catalyst Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, August 7th.
Shares of Catalyst Pharmaceuticals (CPRX) opened at 2.72 on Monday. Catalyst Pharmaceuticals has a 52 week low of $0.73 and a 52 week high of $3.20. The firm’s market cap is $229.99 million. The firm has a 50-day moving average of $2.88 and a 200 day moving average of $1.98.
Several hedge funds have recently made changes to their positions in the stock. OxFORD Asset Management LLP raised its position in Catalyst Pharmaceuticals by 46.2% in the second quarter. OxFORD Asset Management LLP now owns 86,168 shares of the biopharmaceutical company’s stock valued at $238,000 after buying an additional 27,228 shares in the last quarter. Virtu KCG Holdings LLC acquired a new stake in Catalyst Pharmaceuticals during the second quarter valued at approximately $237,000. FMR LLC acquired a new stake in Catalyst Pharmaceuticals during the second quarter valued at approximately $828,000. Vanguard Group Inc. raised its stake in Catalyst Pharmaceuticals by 11.3% in the second quarter. Vanguard Group Inc. now owns 3,348,549 shares of the biopharmaceutical company’s stock valued at $9,242,000 after buying an additional 340,614 shares during the last quarter. Finally, Northern Trust Corp raised its stake in Catalyst Pharmaceuticals by 620.9% in the second quarter. Northern Trust Corp now owns 802,566 shares of the biopharmaceutical company’s stock valued at $2,215,000 after buying an additional 691,238 shares during the last quarter. Hedge funds and other institutional investors own 30.28% of the company’s stock.
Catalyst Pharmaceuticals Company Profile
Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.
Receive News & Ratings for Catalyst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.